DMRA

29.44

2.15% 0.62

Handel nachbörslich: 29.44

Damora Therapeutics Inc (DMRA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$28.82

Offen:

$29.98

24-Stunden-Volumen:

547.17K

Relative Volume:

0.99

Marktkapitalisierung:

$1.81B

Einnahmen:

Nettoeinkommen (Verlust:

$-209.84M

KGV:

-6.442

EPS:

-4.57

Netto-Cashflow:

$-6.73M

1W Leistung:

-10.76%

1M Leistung:

+16.09%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$29.02

$30.90

1-Wochen-Bereich:

$28.25

$34.74

52-Wochen-Spanne:

$16.50

$34.89

Damora Therapeutics Inc Stock (DMRA) Company Profile

Firmenname

Damora Therapeutics Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (599)

Telefon

(781) 281-9020

Adresse

221 CRESCENT STREET, WALTHAM

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

DMRA's Discussions on Twitter

Compare DMRA vs VRTX, REGN, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DMRA Damora Therapeutics Inc	29.44	1.77B	0	-209.84M	-6.73M	-4.57
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-24	Eingeleitet	RBC Capital Mkts	Outperform
2026-03-25	Eingeleitet	Evercore ISI	Outperform
2026-02-17	Eingeleitet	UBS	Buy
2026-01-07	Eingeleitet	Leerink Partners	Outperform
2025-12-01	Eingeleitet	Guggenheim	Buy
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2020-11-23	Eingeleitet	BofA Securities	Buy
2020-11-23	Eingeleitet	Credit Suisse	Outperform
2020-11-23	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten

11:00 AM

DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus

11:00 AM

07:57 AM

H.C. Wainwright reiterates Damora Therapeutics stock rating on device advantage - Investing.com Canada

07:57 AM

07:56 AM

This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

07:56 AM

03:25 AM

Jefferies initiates Damora Therapeutics stock with buy rating By Investing.com - Investing.com Canada

03:25 AM

Jul 26, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat

Jul 26, 2026

Jul 25, 2026

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat

Jul 25, 2026

Damora Therapeutics, Inc. Revenue Breakdown – NASDAQ:DMRA - TradingView

Jul 25, 2026

Jul 22, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat

Jul 22, 2026

DMRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus

Jul 21, 2026

H.C. Wainwright reiterates Buy on Damora Therapeutics stock By Investing.com - Investing.com Canada

Jul 21, 2026

Jul 20, 2026

Damora Therapeutics Completes Cayman Islands Redomestication - TipRanks

Jul 20, 2026

Jul 17, 2026

Damora Therapeutics completes redomestication to Cayman Islands - Investing.com

Jul 17, 2026

Damora Announces Redomestication from Delaware to Cayman Islands - The Manila Times

Jul 17, 2026

Damora Will Keep DMRA Ticker Under New Nasdaq CUSIP July 20 - Stock Titan

Jul 17, 2026

Jul 16, 2026